Congratulations to Dr Jasmine Singh, awarded a PhD scholarship from the Leukaemia Foundation and Haematology Society of Australia and New Zealand
Jasmine’s PhD studies focus on risk factors for development of clonal haematopoiesis of indeterminate potential (CHIP) and the role of inflammation and its consequences with the ASPirin in Reducing Events in the Elderly (ASPREE) study. This NHMRC-funded study is being led by A/Prof Zoe McQuilten and Prof Erica Wood of TRU, and Prof David Curtis of the Australian Centre for Blood Diseases at Monash University.
Congratulations to Dr Allison Mo, awarded the best abstract presentation on patient blood management at BLOOD 2021
Allison presented the results of one of her PhD project studies on changing red cell and platelet transfusion needs in patients with myelodysplastic syndromes: A 15-year Australian population data linkage study. The award is supported by ANZSBT and the National Blood Authority.
Transfusion Research Unit at the BLOOD 2021 conference
At the BLOOD 2021 conference, held virtually from 20-23 September, the TRU team contributed to more than 25 invited, oral abstract and poster presentations, including in the ANZSBT Presidential and the HSANZ Baikie Young Investigator sessions. These covered the spectrum from transfusion medicine (including a plenary lecture on convalescent plasma for COVID-19, results from the Australian/NZ Massive Transfusion Registry, and use of immunoglobulins for patients with blood cancers – the RATIONAL trial) to results of projects from our lymphoma, myeloma, myelodysplasia, aplastic anaemia and other bone marrow failure syndromes, and haemoglobinopathy registries. Many were presented by TRU students or other young investigators. Congratulations to all involved!
Recent publications from the Transfusion Research Unit
REMAP-CAP Investigators: Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2021 Oct 4. doi: 10.1001/jama.2021.18178.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
Aubron C, Hourmant B, Menguy J, Sparrow RL: Transfusion-related respiratory complications in intensive care: A diagnosis challenge. Transfus Clin Biol. 2021 Sep 15:S1246-7820(21)00473-0. doi: 10.1016/j.tracli.2021.09.007.
REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators: Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417.
ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators: Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911.
Arabi YM, Gordon AC, Derde LPG, REMAP-CAP Investigators. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5.
Launch of the WHO Global Patient Safety Action Plan 2021-2030
Professor Erica Wood participated in the official launch of the WHO Global Patient Safety Action Plan 2021-2030 on 4-5 August 2021.
TRU at Serious Hazards of Transfusion Symposium
Professor Erica Wood joined colleagues from around the world at the annual Serious Hazards of Transfusion (SHOT) symposium on 14-15 July 2021, in a panel discussion on the impact of COVID-19 on haemovigilance for hospitals, blood centres and others.
The annual SHOT report for 2020 was launched at the meeting, and is available at shotuk.org
RCPA Pathology Update
A/Prof Zoe McQuilten was invited to speak at the Royal College of Pathologists of Australasia (RCPA) Pathology Update – this year held virtually. Zoe joined Dr James Daly of Australian Red Cross Lifeblood in a plenary session on 4 July 2021 to discuss the use of convalescent plasma for COVID-19.
NHMRC Blood Synergy program PhD scholarships available
The Blood Synergy program is seeking expressions of interest from potential PhD candidates to join the Blood Synergy research that focuses on improving patient outcomes and making better use of blood products. PhD projects should be aligned with the objectives of the Blood Synergy, and in one of the target areas of critical bleeding, critical illness, or blood diseases or immunoglobulin use.
Candidates will ideally have a background in medicine or clinical sciences, and an interest in haematology, transfusion medicine, critical care, emergency/trauma, surgery, and/or health economics.
More information on the Blood Synergy is available at bloodsynergy.org/news
Expressions of interest should be sent to email@example.com by 1 August 2021.
LaRDR at 16th International Congress on Malignant Lymphoma
On behalf of the Lymphoma and Related Diseases Registry (LaRDR), A/Prof Eliza Hawkes and colleagues contributed to an analysis by the International Prospective T-cell project 2.0, presented at the 16th International Congress on Malignant Lymphoma.
LaRDR contributed 159 cases to the total of 594 included in the analysis of these rare and important types of lymphoma.
See: Federico M, Chiattone CS, Prince HM…Hawkes EA…S. Luminari S: Subtypes of mature T and NK cell lymphomas according to 2016 WHO Classification: Preliminary report of the International Prospective T‐Cell Project 2.0. Available at: doi: 10.1002/hon.135_2880.
More information on the Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma is available at clinicaltrials.gov/ct2/show/NCT03964480
MRFF funding for genomics studies in bone marrow failure syndromes
TRU researchers are delighted that their grant application “Diagnosis, discovery and novel phenotype characterisation using multimodal genomics in patients with inherited bone marrow failure and related disorders” has received $2.997 million from the MRFF Genomics Health Futures Mission. This research is a collaboration between many investigators, led by Dr Piers Blombery at the University of Melbourne/Peter MacCallum Cancer Centre, and institutions around Australia, including Prof Erica Wood (CIB) and Dr Lucy Fox (CIC) at Monash University.
The Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry (AAR) will contribute to this important project to improve diagnosis and management for patients with inherited bone marrow failure syndromes and related disorders.
World Blood Donor Day 2021
Prof Erica Wood joined celebrations for World Blood Donor Day on 14-15 June, conveying greetings to the WBDD opening session in Rome in her role as president of the International Society of Blood Transfusion, and attending the WBDD Scientific Symposium.
More information is available at: www.who.int/campaigns/world-blood-donor-day/2021
RATIONAL trial results presented at the European Hematology Association Congress
A/Prof Zoe McQuilten presented the preliminary results of the RATIONAL feasibility trial at the European Hematology Association Congress on 13 June 2021. The results showed that similar proportions of patients receiving immunoglobulin or prophylactic antibiotics were alive and on their assigned treatment arm at 12 months (the study’s primary outcome) and there were no significant differences in time to first major infection, or adverse events.
The trial was funded by the National Blood Authority and supported by the Australasian Leukaemia and Lymphoma Group.
Recent publications from the Transfusion Research Unit
1.Mo A, Stanworth SJ, Shortt J, Wood EM, McQuilten ZK. Red cell transfusions: Is less always best?: How confident are we that restrictive transfusion strategies should be the standard of care default transfusion practice? Transfusion. 2021 Jun 1. doi: 10.1111/trf.16429.
RATIONALISE study grant application successful with the MRFF and NHMRC
The RATIONALISE investigators are delighted that the phase II/III trial (Role of antibiotic therapy or Ig on infections in haematology – Ig Stopping or Extension) was successful with both the MRFF as part of the 2020 Rare Cancers, Rare Diseases and Unmet Need General Grant Opportunity, and with the NHMRC Clinical Trials and Cohort Studies scheme. The trial will be going ahead funded by the NHMRC.
This important trial, part of the Blood Synergy research program, will help address questions about immunoglobulin use, and alternative therapies such as oral antibiotics, for patients with blood cancers in the novel therapies era.
TRU participates in the 2nd Annual Bone Marrow Failure Syndromes Symposium
The TRU team was well represented at the Symposium, 27-29 May, with updates on the Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry (AAR) presented by Dr Lucy Fox, and an update on the DIAAMOND trial of avatrombopag for patients with severe aplastic anaemia presented by A/Prof Stephen Ting. Professor Melissa Southey provided an introduction to the new Australian Marrow Failure Biobank, which is in development through Biobanking Victoria and will link closely with the AAR.
Prof Erica Wood chaired the session on aplastic anaemia, which featured a keynote presentation by Professor Neal Young from the NHLBI.
Survey on decision support for massive transfusion published
This study was conducted by Dr Brenton Sanderson, anaesthetist at Westmead Hospital and PhD student in the Centre for Health Informatics at the Australian Institute of Health Innovation, as part of his program of work to develop a clinical decision support tool for managing massive transfusions. Most anaesthetists responding to the survey reported that they managed relatively few massive transfusions each year, and would welcome and use a clinical decision support tool for this purpose. Dr Sanderson is supervised by Prof Enrico Coiera, Prof Erica Wood and Dr Lise Estcourt.
Ref: Sanderson BJ, Field JD, Estcourt LJ, Wood EM, Coiera EW. Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand anaesthetists. Anaesth Intensive Care. 2021 May 5:310057X20974035. doi: 10.1177/0310057X20974035.
TRU success in Round 5 of the National Blood Sector Research and Development Program
TRU researchers and collaborators were delighted to receive news of funding by the National Blood Authority for two important studies.
The funding application led by A/Prof Zoe McQuilten and Dr Andrew Flint will support Australian and NZ participation in the International Point Prevalence Study of Intensive Care Unit Transfusion Practices – the InPUT study. This study is led from the Netherlands by Prof Alexander Vlaar and colleagues and endorsed by the ANZICS Clinical Trials Group. The results will provide the most up-to-date and comprehensive description of current transfusion practice in ICUs across the country.
Prof Biswadev (Dev) Mitra and colleagues secured funding for a pilot study of prehospital lyophilised (freeze-dried) plasma in the setting of major haemorrhage from trauma.
Details at blood.gov.au/Round-5
Recent publications from the Transfusion Research Unit
TRU on the radio
Prof Erica Wood joined the 3RRR Radiotherapy team to discuss how blood is made, why we have blood groups, and who needs a blood transfusion, including why we need trials of convalescent plasma for COVID-19 in order to know whether this treatment works. Listen via the 3RRR website.
Blood Spotlight on convalescent plasma for COVID-19
Convalescent plasma has been in the news recently. Prof Erica Wood and A/Prof Zoe McQuilten were pleased to write a review article for Blood, the journal of the American Society of Hematology, and invited Dr Lise Estcourt from NHS Blood and Transplant/University of Oxford to join them.
First results from IMPROVE study of immunoglobulin use and infections in patients with myeloma presented at ICHS
Dr Khaili Chai presented the preliminary results from the IMPROVE study at the 21st ICHS Symposium of the International Immunocompromised Host Society (ICHS). Thanks to the organisers and to the participants for some good discussion in the virtual poster session!
IMPROVE (Immunoglobulins in myeloma patients: research into outcomes, variation in practice and epidemiology) is using the Myeloma and Related Diseases Registry (MRDR) to capture data on measures to prevent and manage infection in patients with myeloma. Final follow-up and analysis is now underway. The poster is available here.
Welcome Dr Fiona (Pin-Yen) Chen, Dr Adam Irving, and Fazla Fawwaz
TRU welcomes Dr Fiona Chen as Data Officer to contribute to our expanding number of registry projects and analyses.
Dr Adam Irving joins TRU as part of our collaboration with the Monash Centre for Health Economics through the Blood Synergy program.
And as part of TRU’s collaboration with RMIT Pharmaceutical Sciences program, we’re delighted to welcome Fazla Fawwaz for her professional placement with us in 2021.
Recent publications from the Transfusion Research Unit
The Lymphoma and Related Diseases Registry (LaRDR) reaches 4000 participants
Thanks and congratulations to all the patients and sites participating in LaRDR and supporters of the registry on this wonderful achievement. More information is available at: lardr.org
TRU welcomes Dr Jasmine Singh to the ASPREE CHIP project team
Dr Jasmine Singh is a haematologist and has recently commenced her PhD studies into risk factors for development of clonal haematopoiesis of indeterminate potential (CHIP) and the role of inflammation and its consequences with the ASPirin in Reducing Events in the Elderly (ASPREE) CHIP study.
The NHMRC-funded ASPREE-CHIP study is being led by A/Prof Zoe McQuilten and Prof Erica Wood of TRU, and Prof David Curtis of the Australian Centre for Blood Diseases at Monash University.
National transfusion dataset: new research funded by the Australian Data Partnerships Program
A new national transfusion dataset to collect information on transfusion practice and clinical outcomes will be developed as a collaboration between the Australian and New Zealand Massive Transfusion Registry, Ambulance Victoria, Blood Synergy and national registries for myeloma, lymphoma, bone marrow failure diseases, and critical care. This project (doi: 10.47486/DP708) received investment from the Australian Data Research Commons through the Australian Data Partnerships Program. The ARDC is funded by the National Collaborative Research Infrastructure Strategy (NCRIS).
TRU welcomes Associate Professor Eliza Hawkes
A/Prof Hawkes is an NHMRC fellow and Lymphoma Lead at the Olivia Newton-John Cancer Centre, Austin Health and Eastern Health in Melbourne. After completing Medical Oncology training in Melbourne, she undertook a fellowship at the Royal Marsden Hospital, UK and doctoral studies at Melbourne University. She founded the Australasian Lymphoma Alliance, chairs the ALLG Lymphoma Working Party, and is a member of Steering Committees for Australian National Lymphoma Registry, international Women in Lymphoma group, and EviQ Haematology. Eliza has over 70 publications, and regularly presents at international conferences. She runs a large research program focusing on immune targets in lymphoma.
A/Prof Hawkes has joined the team to provide additional clinical support and expertise to the Lymphoma and Related Diseases Registry.
Our research featured at the American Society of Hematology
The diverse research from our group was well represented at this year’s 62nd ASH Annual Scientific Meeting, held entirely online from 5-8 December:
A/Prof Zoe McQuilten awarded the Vice-Chancellor’s Prize for Excellence by an Early Career Researcher
Congratulations to Zoe, who received this prestigious award for her outstanding research – in addition to being awarded the Dean’s Award this year!
News from the Asia-Pacific Myeloma and Related Diseases Registry
The APAC-MRDR held its annual investigator open meeting online on 2 December, which was very well attended by participants from the region and internationally. The audience enjoyed an update on progress with the registry, and scientific presentations on the potential of ‘liquid biopsy’ in myeloma, and the MRFF-funded EPIMAP (epidemiological modelling) study.
Registry investigators were also delighted to announce that Janssen have confirmed ongoing support for the next 5 years.
More information is available at: apacmrdr.org
The Lymphoma and Related Diseases Registry (LaRDR) holds its annual investigator meeting
More than 70 participants attended the LaRDR Investigator open meeting on 26 November, again this year held in collaboration with the Australasian Lymphoma Alliance. Due to the COVID-19 situation, the meeting was entirely online. It was a pleasure to provide updates on the many projects underway, including those of several young investigators, and our international collaborations. Registry recruitment is nearing 4000 participants.
More information is available at: lardr.org/2020/12/15/alalardr-investigator-meeting-2020
Recent publications from the Transfusion Research Unit
First patient for the REDDS-2 study
After some delays, in part due to the COVID-19 pandemic, the first participant has been randomised to the REDDS-2 study of transfusion for patients with myelodysplastic syndromes. Congratulations to Dr Dorothea Evers and team at Radboud University Medical Centre in Nijmegen, the Netherlands! More information on the study is available at monash.edu/medicine/redds2.
Blood Synergy update
The NHMRC-funded Blood Synergy program team has been working hard through 2020 despite the constraints of the COVID-19 lockdown. More information on the projects, investigators and our collaborators is now available on the new program website bloodsynergy.org or please contact us at firstname.lastname@example.org.
Dr Khaili Chai discusses COVID-19 convalescent plasma in Cochrane review podcast
The latest update of the Cochrane living systematic review has been published:
Chai KL, Valk SJ, Piechotta V, Kimber C, Monsef I Doree C,, Wood EM, Lamikanra A, Roberts DJ, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;Oct 12;10:CD013600. doi: 10.1002/14651858.CD013600.pub3.
Dr Khaili Chai discusses the main findings in a podcast, available on the Cochrane Library website.
IMPROVE study reaches target recruitment
The National Blood Authority-funded IMPROVE (Immunoglobulins in Myeloma Patients: Research into Outcomes, Variation in practice, and Epidemiology) study is studying infections and immunoglobulin use in patients with myeloma. Participants are enrolled through the Myeloma and Related Diseases Registry, and a sub-set of patients are also providing samples for immune profiling studies.
The TRU team, and especially Sabine Albold, IMPROVE project officer, were delighted to reach our target of 300 participants recently. A huge ‘thank-you’ to everyone involved, especially the patients and staff at participating hospitals – and particularly given the COVID-19-related disruptions to many aspects of clinical research.
IMPROVE will provide valuable new Australian data to inform national policy, immunoglobulin stewardship and patient outcomes.
TRU contributes to the October scientific meeting of the Australasian Leukaemia and Lymphoma Group
Research led by the Transfusion Research Unit was featured at the recent ALLG meeting.
Australian and NZ Myeloma and Related Diseases Registry reaches 4000 patients
Congratulations to Wellington Hospital, who recruited the 4000th patient on 30th September 2020, and to the whole MRDR team. This is a wonderful achievement, representing the contributions of patients and staff at 48 sites across Australia and New Zealand, the bi-national steering committee chaired by Professor Andrew Spencer, our funders and supporters, and the MRDR operations team at Monash University. Well done everyone!
International haemovigilance at the China Blood Safety Symposium
Professor Erica Wood joined the Chinese Academy of Medical Sciences, Peking Union Medical College and National Center for Disease Control and Prevention on 19 September 2020 for the First China Blood Safety Symposium, to discuss “International haemovigilance: Status and challenges”.
A/Prof Zoe McQuilten and Dr Allison Mo speak at Transfusion United conference
At the online conference, supported by Lifeblood, ANZSBT, RCPA and HOW, Zoe provided an overview of hospital transfusion services’ responses to COVID-19 which featured in a Vox Sanguinis International Forum. Allison presented data on the changing transfusion needs of patients with myelodysplastic syndromes as part of an analysis of longitudinal data from the Victorian Admitted Episodes Dataset, which forms part of her PhD studies.
Dr Lucy Fox presents at the Maddie’s Vision Patient and Family Forum on Bone Marrow Failure Syndromes
Lucy shared an update on the Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry and the DIAAMOND trial as part of the event on 28th August 2020, which brought together over 200 patients, families, clinicians and scientists.
The full recording of the event is available on YouTube
Professor Erica Wood presents at the NIH/Versiti Red Cell Genotyping Symposium 2020
Hosted by the National Institutes of Health, Versiti Blood Centers and the US Department of Health and Human Services, the 10th annual red cell genotyping symposium was held online on 9 September 2020. Erica delivered the opening lecture “Red cell genotyping for improving patient care and clinical outcomes.”
Australian and NZ Myeloma and Related Diseases Registry holds its annual investigator meeting online
The MRDR was delighted to welcome a large group to its 2020 investigator meeting, this year held online on September 5 as part of the National Myeloma Workshop, with thanks to Myeloma Australia.
Special thanks to guest speakers A/Prof Dennis Petrie from the Centre for Health Economics, speaking about the MRFF-funded myeloma epidemiological modelling study, and Dr Cecily Forsyth from Gosford speaking about participating in the MRDR from private practice. Prof Andrew Spencer delivered the annual update on MRDR activities, and Dr Kim Huynh provided an update on progress with the Asia-Pacific Myeloma Registry (more info at apacmrdr.org).
Dr Karina Brady joins TRU as Blood Synergy Program Manager
TRU welcomes Karina as the new Program Manager for the Blood Synergy Program – an NHMRC-funded program addressing Australia’s national transfusion research priorities. She coordinates Blood Synergy activities and provides leadership, project and strategic support to the Synergy grant investigators team. Karina has a background in scientific and clinical research, and a PhD in neurophysiology. Prior to joining TRU, she was a Laboratory Head/Senior Research Fellow at the University of Melbourne, and Project Lead at the HEARing Cooperative Research Centre. She has experience in a broad range of preclinical, multidisciplinary and clinical studies, with particular focus on neuroscience, hearing loss and cochlear implant technology.
Recent publications from the Transfusion Research Unit
Convalescent plasma trials for COVID-19 open to recruitment in Australia
Convalescent plasma to treat SARS-CoV-2 (COVID-19) infection is now being used as part of the Australasian COVID-19 Trial (ASCOT) and the international Randomised, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) trial.
The Australian Convalescent Plasma Study, led A/Prof Zoe McQuilten and supported by the Medical Research Future Fund, is a collaboration between the Monash University Transfusion Research Unit/Blood Synergy investigators, Australian and New Zealand Intensive Care Research Centre, REMAP-CAP and ASCOT investigators, and Australian Red Cross Lifeblood.
A big ‘thank-you’ to the blood donors and the hard-working teams who have made these trials a reality.
More information is available at: abc.net.au/news/2020-08-06/coronavirus-treatments-and-covid19-cure-research/12527034 and doherty.edu.au/news-events/news/convalescent-plasma-treatment-for-covid-19-introduced-to-ascot-and-remap-cap-trials
Recent publications from the Transfusion Research Unit
Flint AWJ, McQuilten ZK, Bailey M, Smith JA, Wood EM, Reade MC. Preoperative identification of cardiac surgery patients at risk of platelet transfusion: the Australian Cardiac Surgery Platelet Transfusion (ACSePT) risk prediction tool. Transfusion (online 5 August 2020). doi.org/10.1111/trf.15990.
Mahady SE, Margolis KL, Chan AT, Polekhina G, Woods RL, Wolfe R, Nelson MM, Lockery J, Wood EM, Reid CM, Ernst ME, Murray AM, Le LTP, McNeil JJ: Major gastrointestinal bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut 2020;0:1–8. doi:10.1136/gutjnl-2020-321585 (online 3 August).
Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600. doi: 10.1002/14651858.CD013600.pub2.PMID: 32648959.
Alves D, Curvello R, Henderson E, Kesarwani V, Walker JA, Leguizamon SC, McLiesh H, Raghuwanshi VS, Samadian H, Wood EM, McQuilten ZK, Graham M, Wieringa M, Korman TM, Scott TS, Banaszak Holl MM, Garnier G, Corrie SR: Rapid gel-card agglutination assays for serological analysis following SARS-CoV-2 infection in humans. ACS Sensors Jul 16. doi: 10.1021/acssensors.0c01050.
Al-Riyami AZ, Schäfer R, van der Berg K, Bloch EM, Estcourt EJ, Goel R, Hindawi S, Josephson C, Land K, McQuilten ZK, Spitalnik S, Wood EM, Devine DV and So-Osman C: Clinical use of convalescent plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities. Vox Sanguinis 15 Jun 2020. doi: 10.1111/vox.12973.
Ashby M, Attwood L, Graham M, Wood E: Challenges for pathology laboratories during the COVID-19 pandemic: the view from Australia. Bulletin of the Royal College of Pathologists (UK), 2020;191;151-152. Available at: rcpath.org/profession/publications/college-bulletin/july-2020/covid-19-challenges-for-pathology-laboratories-during-the-covid-19-pandemic-the-view-from-australia.html.
Yazer MH, Jackson B, Pagano M, Rahimi-Levene N, Peer V, Bueno JL, Jackson RP, Shan H, Amorim-Filho L, Lopes ME, Boquimpani C, Sprogøe U, Bruun MT, Titlestad K, Rushford K, Wood EM, McQuilten ZK, de Angelis V, Delle Donne M, Murphy M, Staves J, Cho D, Nakamura F, Hangaishi A, Callum J, Lin Y, Mogaddam M, Gharehbaghian A, Lozano M. Vox Sanguinis International Forum on transfusion services about response to COVID-19. Vox Sanguinis 2020 May 8. doi: 10.1111/vox.12943.
A new, rapid test for COVID-19 antibody detection
In collaboration with Monash BioPRIA and Chemical Engineering, TRU researchers have contributed to development of a new assay for SARS-CoV-2 antibodies. The world-first research was published on 17 July 2020 in the prestigious journal ACS Sensors. The test incubates patient plasma or serum with reagent red blood cells previously coated with short peptides representing pieces of the SARS-CoV-2 virus, and uses red cell agglutination to determine a positive or negative result. The new assay, using column agglutination cards and automated readers already widely available in pathology laboratories, gives results in 20 minutes and could be used for high-throughput screening. “We found that by producing bioconjugates of anti-D-IgG and peptides from SARS-CoV-2 spike protein, and immobilising these to RRBCs, selective agglutination in gel cards was observed in the plasma collected from patients recently infected with SARS-CoV-2 in comparison to healthy plasma and negative controls,” said Professor Gil Garnier, Director of BioPRIA.
To download a copy of the research, please visit doi.org/10.1021/acssensors.0c01050
To watch a video of this research in action, please visit youtu.be/9WBQUC43u9Q
The Australian Haemoglobinpathy Registry (HbR) reached an important milestone recently, with more than 500 participants now contributing from 9 hospitals across Australia.
The goal of the HbR is to better understand the picture of haemoglobinopathies in Australia, with the aim to improve outcomes for patients, families and the community. Approximately half the HbR participants to date have beta thalassaemia major, and about one-third have a sickling disorder. Additional hospitals have ethics approval to participate and are anticipated to commence recruitment during 2020.
The HbR is currently conducting a study of diagnoses, management and outcomes for Australian adults with sickle cell disease, and this will be extended to paediatric patients during 2020.
Thank you to all the participants, staff and investigators around Australia contributing to the HbR! If your hospital is interested in joining the registry, or you have questions about the HbR please contact the Monash team at:
Prof Erica Wood becomes president of the International Society of Blood Transfusion
Congratulations to Professor Erica Wood who took up her role as president of the International Society of Blood Transfusion on 9 June 2020, for a two-year term. Due to the COVID-19 pandemic, the first time, the ISBT General Assembly was held by webinar – a first for the Society. For more information: isbtweb.org/about-isbt/board-of-directors
Monash researchers awarded MRFF funding for epidemiological modelling study of myeloma treatments
Congratulations to A/Prof Zoe McQuilten and the team of researchers from SHPHPM (Dr Elizabeth Moore, Dr Cameron Wellard, Prof Erica Wood), Alfred Health (Prof Andrew Spencer) and the Monash Centre for Health Economics (Prof Tony Harris, A/Prof Dennis Petrie and Dr Laura Fanning) who were awarded funding from the MRFF through the call for Targeted Health System and Community Organisation Research. The group will use data from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR), in combination with national population level data on myeloma incidence, to model estimated transplant-eligible and ineligible myeloma patient populations at different treatment stages and according to performance status. The models will be validated with external, international datasets and input from a national and international network of clinical experts.
TREATT trial update
The TREATT trial is reopened to recruitment after a COVID-related hiatus affecting all participating Australian and UK hospitals. In a briefing for Australian investigators on 9 June, trial coordinator Amber Degelia updated the group on recent activities. Well done to the team at Monash Medical Centre who recruited the first post-COVID participant. Only 57 more patients are needed to reach the goal of 616 total participants – the finish line is in sight! Thank you to all the patients and staff working on TREATT across the country.
Convalescent plasma study for COVID-19 funded by the MRFF
Congratulations to A/Prof Zoe McQuilten and colleagues, whose SARS-CoV-2 Australian Convalescent Plasma Study has been awarded support from the Medical Research Future Fund (Antiviral Development for COVID-19 Funding). The study is a collaboration between the Australian and New Zealand Intensive Care Research Centre, the Randomised, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) investigators, the Australasian COVID-19 Trial (ASCOT) investigators, the Monash University Transfusion Research Unit/Blood Synergy investigators, and the Australian Red Cross Lifeblood.
Myeloma and lymphoma registries highlighted at the National Oncology Alliance/Rare Cancers Australia workshop
Professor Andrew Spencer, chair of the Myeloma and Related Diseases Registry steering committee, and Professor Stephen Opat, chair of the Lymphoma and Related Diseases Registry steering committee, shared their experiences of collecting and analysis of ‘real world’ data using registries for blood cancers at the NOA Vision 20-30 workshop. They emphasised the value of these data for patients, clinicians, governments and industry, and how registry data complement the information provided by clinical trials. More information on these registries is available at: www.mrdr.net.au and www.lardr.org
TRU contributes to Cochrane rapid review of convalescent plasma or hyperimmune immunoglobulin for COVID-19, and to guidelines for managing haematology/ oncology patients during the COVID-19 pandemic
Haematologist and TRU PhD student Dr Khaili Chai and colleagues contributed to a Cochrane rapid review of convalescent plasma or hyperimmune immunoglobulins for COVID-19. The study was published on 14th May 2020. The work will be updated as a living review, as more data on the safety and efficacy of these therapies become available.
Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, Estcourt LJ, Skoetz N. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a rapid review. Cochrane Database of Systematic Reviews 2020, Issue 5. Art. No.: CD013600. DOI: 10.1002/14651858.CD013600.
A/Prof Zoe McQuilten and colleagues developed guidance for clinicians managing haematology patients during the pandemic. The recommendations were endorsed by a large number of professional organisations across Australia and New Zealand.
Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, Conyers R, Haeusler GM, Hardie C, Jackson C, Lane SW, Middlemiss T, Mollee P, Mulligan SP, Ritchie D, Ruka M, Solomon B, Szer J, Thursky KA, Wood EM, Worth LJ, Yong MK, Slavin MA, Teh BW. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust. 2020 Jun;212(10):481-489.
NHMRC Investigator Grant for A/Prof Zoe McQuilten
Well done, Zoe! A/Prof Zoe McQuilten has been awarded an NHMRC Investigator Grant for her research: “Improving patient outcomes through better use of blood products”. The highly competitive award will support Zoe’s research for 5 years from 2021.
My-PROMPT study results published
Congratulations to Dr Elizabeth Moore and colleagues on publication of the MY-PROMPT study results. This pilot randomized controlled trial showed that it was feasible to collect patient-reported outcomes on quality-of-life issues important to patients with myeloma, and provide real-time feedback of these results to clinicians. The study’s findings will help inform a future study in this area.
Moore EM, King TA, Wood EM, Ruseckaite R, Klarica D, Spencer A, Ho PJ, Quach H, Prince HM, McQuilten ZK. Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial. Am J Hematol 2020 Apr 3. doi: 10.1002/ajh.25815.
Fiona Stanley Prize for NHMRC Synergy Grant
Professor Erica Wood was delighted to receive the inaugural Fiona Stanley Prize for the top-ranked 2019 Synergy grant: “Addressing Australia’s national transfusion research priorities”. It was extra-special that Professor Stanley herself presented the award at the NHMRC Research Excellence Awards dinner, held in Canberra in March 2020.
Victorian Cancer Agency Clinical Research Fellowship for A/Prof Zoe McQuilten
Congratulations to A/Prof Zoe McQuilten who has been awarded a 5-year Victorian Cancer Agency Clinical Research Fellowship. This funding will support her work on the IMPACT program: Immunoglobulin replacement versus Prophylactic Antibiotics to prevent infections in patients with hypogammaglobulinaemia due to blood Cancers Trials.
Immunoglobulin products made from donated plasma are routinely used to supplement antibody levels to prevent infections for patients with blood cancers such as myeloma and lymphoma. However, treatment of these disorders has changed dramatically since the original studies on immunoglobulin replacement were conducted, and there is little up-to-date evidence on optimal use of these blood products or alternative therapies. Zoe will continue and expand the TRU clinical trials program to identify which patients are most likely to benefit from immunoglobulin and whether alternatives, such as antibiotics, could also be effective, aiming to improve patient outcomes, reduce risks and costs, and improve stewardship of these precious community resources.
NHMRC Synergy Grant kicks off with planning day
The investigators of the successful NHMRC Synergy grant met for the first time on 21st February to get underway with the 5-year program of work: “Addressing Australia’s national transfusion research priorities.” Main themes of the research include major haemorrhage and massive transfusion, prevention and management of bleeding and anaemia in patients with blood cancers, bleeding and platelet transfusions in patients with critical illness, and efficient and effective use of immunoglobulins.
Pictured left: Investigators and guests
Absent: Prof Jamie Cooper, A/Prof Craig French, Prof Enrico Coiera, Prof Simon Stanworth
Recent publications from the Australian and New Zealand Massive Transfusion Registry
Congratulations to the ANZ-MTR team on two recent publications:
“Haematological features, transfusion management and outcomes of massive obstetric haemorrhage: findings from the Australian and New Zealand Massive Transfusion Registry” was published in the British Journal of Haematology in February 2020, led by Dr Masa Lasica and A/Prof Rosemary Sparrow.
“Clinical coding data algorithm to categorize type of gastrointestinal bleeding as a primary reason for massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry”, was published online in Vox Sanguinis in November 2019, led by Dr Shara Ket and A/Prof Rosemary Sparrow.
TRU welcomes new staff and students for 2020
TRU welcomes Sabine Albold who joins the Myeloma and Related Diseases Registry (MRDR) team as a Research Officer, and Natthida Khajornjiraphan and Rosalyn Cao who are working with us on 6-month projects using the MRDR for their Master of Clinical Research studies. We also welcome our new PhD student Dr Khaili Chai, haematologist, who will be studying immunoglobulin use in patients with blood cancers. Kamal Al-Helou joins us for a professional placement year as part of the RMIT Pharmaceutical Sciences program – the fourth year TRU has hosted a student. Dr Mike Shipton from Peter MacCallum Cancer Centre and Dr Adi Tedjaseputra from Monash Health, both training in haematology, are working on projects using the Lymphoma and Related Diseases Registry (LaRDR).
Prof Erica Wood participates in the APEC Life Science Innovation Forum on Blood Screening and Processing Centralisation through development of Centres of Excellence
Erica was an invited speaker at the APEC meeting held in Yogyakarta, Indonesia on 4-5 February 2020, which brought together experts in blood safety from a number of APEC countries. She gave four presentations at the forum and its associated ‘basic-advanced course in transfusion’ for clinicians, covering special considerations for female blood donors, international haemovigilance, engaging with clinicians, and patient blood management.
Transfusion Research Unit NHMRC Synergy Grant success
Congratulations to all investigators and supporters on the award of a $5 million NHMRC Synergy Grant: “Addressing Australia’s national transfusion research priorities”.
The research focusses on two major themes:
The research will include observational studies and interventional trials of new approaches and new blood products.
The Chief Investigators are: Prof Erica Wood, A/Prof Zoe McQuilten, Prof Peter Cameron, Prof D Jamie Cooper, Prof Michael Reade, Ms Alisa Higgins, Prof Judith Trotman, Prof Simon Stanworth and Ms Linley Bielby. The Associate Investigators are: Prof Enrico Coiera, Dr Andrew Flint, A/Prof Craig French, Prof Anthony Harris, Dr Allison Mo, A/Prof John Reynolds, Dr Brenton Sanderson, and Dr Rosemary Sparrow.
Prof Erica Wood attends meeting of World Health Organization anaemia guideline development group
WHO has convened a new guideline development group on the use and interpretation of haemoglobin concentrations for assessing anaemia in both individuals and populations. The multi-disciplinary group met for the first time in Barcelona in November 2019 to identify available evidence and priorities for research and implementation to address these important issues.